# AtriAN Medical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atrian-medical

- Industry: Medical Devices & Equipment
- Headquarters: Galway, Ireland
- Website: www.atrianmedical.com
- Total disclosed funding: $2.5M
- Latest round: Seed (Sep 30, 2019)
- Investors on record: 5

## About

AtriAN Medical Ltd. is focused on developing advanced cardiac therapies, specifically targeting atrial fibrillation treatment through innovative pulsed field ablation technology.Founded in 2017 and headquartered in Galway, Ireland, AtriAN Medical Ltd. specializes in cardiac medical solutions. The founders, Barry O'Brien and Ken Coffey, have experience in the medical technology sector. In September 2019, the company raised EUR 2.3 million in Seed funding, with investors including Atlantic Bridge, Enterprise Ireland, Mayo Clinic Ventures, and Western Development Commission. To date, AtriAN has completed one deal, reflecting its initial steps in the medical device market.AtriAN Medical Ltd. specializes in the development of innovative cardiac therapies, focusing primarily on the treatment of atrial fibrillation (AF) through its proprietary technology known as Pulsed Field Ablation (PFA). The core product offering includes a cardiac-customized pulsed field generator and specialized catheter systems designed for epicardial treatment of AF, utilizing gentle, non-thermal energy to selectively ablate ganglionated plexi located on the heart's epicardial surface. This approach aims to restore natural heart rhythm by addressing the hyperactive signals responsible for arrhythmias while sparing surrounding myocardial tissue. AtriAN's technology is particularly relevant for patients undergoing cardiac surgeries and those seeking alternatives to traditional thermal ablation methods. The company's products are primarily targeted at healthcare facilities and cardiac specialists in markets including Europe and North America, where there is a growing demand for effective and durable solutions for AF management.AtriAN Medical's revenue model is based on the sale of its advanced medical devices and technology solutions to healthcare providers, particularly hospitals and cardiac surgery centers. Transactions typically occur through direct sales and partnerships with medical institutions. The company has raised EUR 2.3 million in funding to support its research and development initiatives and is positioned for future growth as it prepares to enter first-in-human clinical trials and expand its product offerings. While specific pricing details for individual products have not been disclosed, the company's innovative solutions, notably its PFA systems, are expected to be priced competitively within the medical device market, reflecting their advanced technology and potential clinical benefits for atrial fibrillation treatment.AtriAN Medical Ltd. plans to utilize its recent Seed funding of EUR 2.3 million, raised in September 2019, to support its growth initiatives, including upcoming product launches and clinical trials. The company aims to enhance its product line with new devices designed for atrial fibrillation treatment, targeting a market release within the next 24 months. Additionally, AtriAN is focused on expanding its presence in North America and Europe, leveraging partnerships with healthcare institutions to facilitate access to its innovative cardiac therapies.

## Funding rounds

- Seed, Sep 30, 2019, $2.5M — Mayo Clinic Ventures, Atlantic Bridge, Enterprise Ireland, Western Development Commission, Xenium Capital

## Investors

- Mayo Clinic Ventures (https://capitalatlas.ai/funds/mayo-clinic-ventures) — Seed
- Atlantic Bridge (https://capitalatlas.ai/funds/atlantic-bridge) — Seed
- Enterprise Ireland (https://capitalatlas.ai/funds/enterprise-ireland) — Seed
- Western Development Commission (https://capitalatlas.ai/funds/western-development-commission) — Seed
- Xenium Capital (https://capitalatlas.ai/funds/xenium-capital) — Seed